On a deal spree, Mallinckrodt bags Sucampo and two late-stage rare disease drugs for $1.2B
The biotech year is ending with a light bang on the M&A front.
Suffering from a rep based more on exploiting markets than developing new drugs, Mallinckrodt $MNK is beefing up its pipeline of rare disease drugs with the $1.2 billion buyout of Sucampo $SCMP. The deal delivers one marketed drug — Amitiza (lubiprostone) for constipation — as well as two experimental ones, both in late-stage development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.